Biogen Inc. (NASDAQ:BIIB) is one of the best stem cell therapy stocks to buy. On April 22, Biogen Inc. (NASDAQ:BIIB) was upgraded to Buy from Neutral by UBS, with the firm adjusting the price target on the stock to $225 from $185. It told investors in a research note that it has increased conviction on the company’s pipeline catalysts coming over the next 12-15 months, adding that the readouts should move the stock higher going into 2027.
Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying
UBS also stated that it sees upside on the BIIB080 tau data this summer, adding that the “real upside catalyst” in fiscal Q4 is the Phase III litifilimab data in systemic lupus. It contended that Biogen Inc. (NASDAQ:BIIB) offers a “window of pipeline catalysts” and is an “under-owned out-of- favor stock that trades at a discount to large-cap peers”.
In a separate development, Wells Fargo upgraded Biogen Inc. (NASDAQ:BIIB) to Overweight from Equal Weight on April 20, lifting the price target on the stock to $250 from $200.
Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases worldwide. Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
While we acknowledge the potential of BIIB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.